Wednesday, July 12, 2017 6:14:32 AM
"We view the Novartis briefing documents as suggestive of FDA support for approval, and beneficial to all CART players. Importantly, we will listen carefully to any details on manufacturing, which may benefit KITE. We believe safety for the CART class, specifically CRS, will be carefully managed, and will not prevent a positive panel vote and FDA approval."
Canaccord analyst John Newman reiterated his "Buy" rating and $115 price target on Kite Pharma Tuesday, saying that the briefing documents from Novartis thus far are positive.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM